Vyome Therapeutics Inc.
https://www.vyometx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vyome Therapeutics Inc.
BridgeBio May See Quicker Market Entry For Muscular Dystrophy Drug
BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.
Scrip Asks…What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances
Evolving challenges will keep the COVID-19 pipeline active, while oncology, immunology and CNS are areas also expected to see much progress in 2022. Industry executives look forward to the year in therapeutic R&D.
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Venture Funding Deals, July – August 2016
Ambrx, Arcus, Cleave Biosciences, InflaRx, MonoSol Rx, Nevakar and Tioma Therapeutics were among firms raising more than $30m in venture funding in July and August. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive review of emerging biopharmaceutical companies that have received venture funding during the past two months.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
-
Drug Delivery
- Topical Delivery
-
Biotechnology
- Drug Discovery Tools
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Vyome Biosciences Private Limited
- Vyome Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice